MEDICINES R US LIMITED


2021-06-012022-05-312022-05-31false07258925MEDICINES R US LIMITED2023-02-1647730iso4217:GBPxbrli:pure072589252021-06-01072589252022-05-31072589252021-06-012022-05-31072589252020-06-01072589252021-05-31072589252020-06-012021-05-3107258925bus:SmallEntities2021-06-012022-05-3107258925bus:AuditExempt-NoAccountantsReport2021-06-012022-05-3107258925bus:FullAccounts2021-06-012022-05-3107258925bus:PrivateLimitedCompanyLtd2021-06-012022-05-3107258925core:WithinOneYear2022-05-3107258925core:AfterOneYear2022-05-3107258925core:WithinOneYear2021-05-3107258925core:AfterOneYear2021-05-3107258925core:ShareCapital2022-05-3107258925core:SharePremium2022-05-3107258925core:RevaluationReserve2022-05-3107258925core:OtherReservesSubtotal2022-05-3107258925core:RetainedEarningsAccumulatedLosses2022-05-3107258925core:ShareCapital2021-05-3107258925core:SharePremium2021-05-3107258925core:RevaluationReserve2021-05-3107258925core:OtherReservesSubtotal2021-05-3107258925core:RetainedEarningsAccumulatedLosses2021-05-3107258925core:LandBuildings2022-05-3107258925core:PlantMachinery2022-05-3107258925core:Vehicles2022-05-3107258925core:FurnitureFittings2022-05-3107258925core:OfficeEquipment2022-05-3107258925core:NetGoodwill2022-05-3107258925core:IntangibleAssetsOtherThanGoodwill2022-05-3107258925core:ListedExchangeTraded2022-05-3107258925core:UnlistedNon-exchangeTraded2022-05-3107258925core:LandBuildings2021-05-3107258925core:PlantMachinery2021-05-3107258925core:Vehicles2021-05-3107258925core:FurnitureFittings2021-05-3107258925core:OfficeEquipment2021-05-3107258925core:NetGoodwill2021-05-3107258925core:IntangibleAssetsOtherThanGoodwill2021-05-3107258925core:ListedExchangeTraded2021-05-3107258925core:UnlistedNon-exchangeTraded2021-05-3107258925core:LandBuildings2021-06-012022-05-3107258925core:PlantMachinery2021-06-012022-05-3107258925core:Vehicles2021-06-012022-05-3107258925core:FurnitureFittings2021-06-012022-05-3107258925core:OfficeEquipment2021-06-012022-05-3107258925core:NetGoodwill2021-06-012022-05-3107258925core:IntangibleAssetsOtherThanGoodwill2021-06-012022-05-3107258925core:ListedExchangeTraded2021-06-012022-05-3107258925core:UnlistedNon-exchangeTraded2021-06-012022-05-3107258925core:MoreThanFiveYears2021-06-012022-05-3107258925core:Non-currentFinancialInstruments2022-05-3107258925core:Non-currentFinancialInstruments2021-05-3107258925dpl:CostSales2021-06-012022-05-3107258925dpl:DistributionCosts2021-06-012022-05-3107258925dpl:AdministrativeExpenses2021-06-012022-05-3107258925core:LandBuildings2021-06-012022-05-3107258925core:PlantMachinery2021-06-012022-05-3107258925core:Vehicles2021-06-012022-05-3107258925core:FurnitureFittings2021-06-012022-05-3107258925core:OfficeEquipment2021-06-012022-05-3107258925core:NetGoodwill2021-06-012022-05-3107258925core:IntangibleAssetsOtherThanGoodwill2021-06-012022-05-3107258925dpl:GroupUndertakings2021-06-012022-05-3107258925dpl:ParticipatingInterests2021-06-012022-05-3107258925dpl:GroupUndertakingscore:ListedExchangeTraded2021-06-012022-05-3107258925core:ListedExchangeTraded2021-06-012022-05-3107258925dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-06-012022-05-3107258925core:UnlistedNon-exchangeTraded2021-06-012022-05-3107258925dpl:CostSales2020-06-012021-05-3107258925dpl:DistributionCosts2020-06-012021-05-3107258925dpl:AdministrativeExpenses2020-06-012021-05-3107258925core:LandBuildings2020-06-012021-05-3107258925core:PlantMachinery2020-06-012021-05-3107258925core:Vehicles2020-06-012021-05-3107258925core:FurnitureFittings2020-06-012021-05-3107258925core:OfficeEquipment2020-06-012021-05-3107258925core:NetGoodwill2020-06-012021-05-3107258925core:IntangibleAssetsOtherThanGoodwill2020-06-012021-05-3107258925dpl:GroupUndertakings2020-06-012021-05-3107258925dpl:ParticipatingInterests2020-06-012021-05-3107258925dpl:GroupUndertakingscore:ListedExchangeTraded2020-06-012021-05-3107258925core:ListedExchangeTraded2020-06-012021-05-3107258925dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2020-06-012021-05-3107258925core:UnlistedNon-exchangeTraded2020-06-012021-05-3107258925core:NetGoodwill2022-05-3107258925core:IntangibleAssetsOtherThanGoodwill2022-05-3107258925core:LandBuildings2022-05-3107258925core:PlantMachinery2022-05-3107258925core:Vehicles2022-05-3107258925core:FurnitureFittings2022-05-3107258925core:OfficeEquipment2022-05-3107258925core:AfterOneYear2022-05-3107258925core:WithinOneYear2022-05-3107258925core:ListedExchangeTraded2022-05-3107258925core:UnlistedNon-exchangeTraded2022-05-3107258925core:ShareCapital2022-05-3107258925core:SharePremium2022-05-3107258925core:RevaluationReserve2022-05-3107258925core:OtherReservesSubtotal2022-05-3107258925core:RetainedEarningsAccumulatedLosses2022-05-3107258925core:NetGoodwill2021-05-3107258925core:IntangibleAssetsOtherThanGoodwill2021-05-3107258925core:LandBuildings2021-05-3107258925core:PlantMachinery2021-05-3107258925core:Vehicles2021-05-3107258925core:FurnitureFittings2021-05-3107258925core:OfficeEquipment2021-05-3107258925core:AfterOneYear2021-05-3107258925core:WithinOneYear2021-05-3107258925core:ListedExchangeTraded2021-05-3107258925core:UnlistedNon-exchangeTraded2021-05-3107258925core:ShareCapital2021-05-3107258925core:SharePremium2021-05-3107258925core:RevaluationReserve2021-05-3107258925core:OtherReservesSubtotal2021-05-3107258925core:RetainedEarningsAccumulatedLosses2021-05-3107258925core:NetGoodwill2020-06-0107258925core:IntangibleAssetsOtherThanGoodwill2020-06-0107258925core:LandBuildings2020-06-0107258925core:PlantMachinery2020-06-0107258925core:Vehicles2020-06-0107258925core:FurnitureFittings2020-06-0107258925core:OfficeEquipment2020-06-0107258925core:AfterOneYear2020-06-0107258925core:WithinOneYear2020-06-0107258925core:ListedExchangeTraded2020-06-0107258925core:UnlistedNon-exchangeTraded2020-06-0107258925core:ShareCapital2020-06-0107258925core:SharePremium2020-06-0107258925core:RevaluationReserve2020-06-0107258925core:OtherReservesSubtotal2020-06-0107258925core:RetainedEarningsAccumulatedLosses2020-06-0107258925core:AfterOneYear2021-06-012022-05-3107258925core:WithinOneYear2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:CostValuation2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-06-012022-05-3107258925core:Non-currentFinancialInstrumentscore:CostValuation2022-05-3107258925core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-05-3107258925core:Non-currentFinancialInstrumentscore:CostValuation2021-05-3107258925core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-05-3107258925core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-05-3107258925core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-05-3107258925core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-05-3107258925core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-05-3107258925core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-05-3107258925core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-05-3107258925core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-05-3107258925bus:Director12021-06-012022-05-3107258925bus:Director22021-06-012022-05-3107258925core:FurnitureFittingsToolsEquipment2021-05-3107258925core:FurnitureFittingsToolsEquipment2022-05-3107258925core:FurnitureFittingsToolsEquipment2021-06-012022-05-31

MEDICINES R US LIMITED

Registered Number
07258925
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2022

MEDICINES R US LIMITED
Company Information
for the year from 1 June 2021 to 31 May 2022

Directors

A K Sharma
Mrs G Sharma

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

07258925 (England and Wales)
MEDICINES R US LIMITED
Balance Sheet as at
31 May 2022

Notes

2022

2021

£

£

£

£

Fixed assets
Tangible assets51,77518,323
Investments6-100
1,77518,423
Current assets
Stocks830,59430,780
Debtors9240,340316,910
Cash at bank and on hand320,469180,995
591,403528,685
Creditors amounts falling due within one year10(237,600)(283,968)
Net current assets (liabilities)353,803244,717
Total assets less current liabilities355,578263,140
Net assets355,578263,140
Capital and reserves
Called up share capital100100
Profit and loss account355,478263,040
Shareholders' funds355,578263,140
  • The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
  • The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
  • The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
  • These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company’s profit and loss account.
The financial statements were approved and authorised for issue by the Board of Directors on 16 February 2023, and are signed on its behalf by:
A K Sharma
Director
Registered Company No. 07258925
MEDICINES R US LIMITED
Notes to the Financial Statements
for the year ended 31 May 2022

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Accounting policies
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery25
Fixtures and fittings25
Stocks policy
Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Taxation policy
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Investments policy
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
4.Employee information

20222021
Average number of employees during the year55
5.Property, plant and equipment

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 June 2181,49961682,115
At 31 May 2281,49961682,115
Depreciation and impairment
At 01 June 2163,38141163,792
Charge for year16,39415416,548
At 31 May 2279,77556580,340
Net book value
At 31 May 221,724511,775
At 31 May 2118,11820518,323
6.Fixed asset investments

Investments in groups1

Total

££
Cost or valuation
At 01 June 21100100
Disposals(100)(100)
Net book value
At 31 May 22--
At 31 May 21100100

Notes

1Investments in group undertakings and participating interests
7.Description of nature of transactions and balances with related parties
Amounts owed by group undertakings relates to Medicines 4U Ltd £92,071 (2021: £87,275), this is the parent company. Included in other debtors is £1,500 (2021: £1,500) this relates to Medicines Direct Ltd, a company where the directors; A K Sharma and G Sharma are also directors and shareholders. Included in other creditors is the director's current account credit balance of £6,149 (2021: £63) this relates to A K Sharma.
8.Stocks

2022

2021

££
Finished goods30,59430,780
Total30,59430,780
9.Debtors

2022

2021

££
Trade debtors / trade receivables117,996204,970
Amounts owed by group undertakings92,07187,275
Other debtors25,74523,556
Prepayments and accrued income4,5281,109
Total240,340316,910
10.Creditors within one year

2022

2021

££
Trade creditors / trade payables204,777220,013
Taxation and social security21,43135,490
Other creditors11,01528,465
Accrued liabilities and deferred income377-
Total237,600283,968